Merck KGaA’s Cladribine capsules gain FDA fast track for rare neuromuscular disorder

Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs

Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure

Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension

The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks

Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment

This is the first and only subcutaneous immune checkpoint inhibitor available in Europe

Merck to acquire Cidara Therapeutics for $9.2 billion

Diversifying its portfolio to include late-phase antiviral agent

Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

Merck Foundation launches $22 million initiative to improve cardiovascular care in US

Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country

Merck’s Capvaxive shows strong momentum amid industry vaccine decline

Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market

Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors

Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile